Previous 10 | Next 10 |
2024-03-08 09:47:01 ET Genius Sports Limited (GENI) GENI is trading DOWN for the last 4 days, and it at trading at $6.26 with volume of 1,145,622 and a one day change of $-0.03 (-0.54%). Genius Sports Limited has a 52-week low of 3.55 and a 52-week high of $8.45. The business's 50-d...
BOSTON, March 07, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in...
PYX-201, an EDB+FN-specific tumor stroma-targeting ADC, demonstrates potent anti-tumor efficacy across multiple human cancers in PDX tumor models The PYX-201 target EDB+FN is found overexpressed across multiple human solid tumor types BOSTON, March 05, 2024 (GLOBE NEWSWIRE) -- Pyx...
BOSTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced that it has agreed to sell 8,849,371 shares of its common stock a...
2024-01-29 16:59:37 ET Gainers: Sanmina Corporation ( SANM ) +15% . Woodward ( WWD ) +7% . F5 ( FFIV ) +7% . Super Micro Computer ( SMCI ) +6% . Alpine Immune Sciences ( ALPN ) +4% . Losers: J-Long Group ( J...
2024-01-26 09:45:09 ET Pyxis Oncology Inc. (PYXS) PYXS is trading UP for the last 5 days, and it at trading at $3.19 with volume of 3,663,280 and a one day change of $0.03 (0.92%). Pyxis Oncology Inc. has a 52-week low of 1.35 and a 52-week high of $6.92. The business's 50-day movin...
2024-01-23 08:24:49 ET Rail Vision ( RVSN ) +29% . TKO Group Holdings ( TKO ) +19% . vTv Therapeutics ( VTVT ) +18% . Bit Brother ( BETS ) +13% . Jeffs Brands ( JFBR ) +10% . Rumble ( RUM )...
2024-01-17 20:15:07 ET Summary Pyxis Oncology is a biotech company focused on developing immunotherapies for cancer treatment. Their most advanced pipeline project is sotigalimab, a CD40 agonist, which has shown promising results in melanoma and liposarcoma. The company has en...
2024-01-04 16:19:31 ET Gainers: Molecular Partners ( MOLN ) +14% . Sutro Biopharma ( STRO ) +9% . Ribbon Communications ( RBBN ) +7% . Resources Connection ( RGP ) +7% . Pyxis Oncology ( PYXS ) +6% . Losers: 89bio ( ETN...
2023-12-08 10:00:17 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Bluebird bio, ...
News, Short Squeeze, Breakout and More Instantly...
BOSTON, June 10, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, today announced the appointment of Michael A. Metzger to its Board of Directors, effecti...
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a...
PYX-201 Phase 1 trial clinical readout on track for fall of 2024 Executive Leadership Team expanded with the appointment of Stephen Worsley as Senior Vice President, Chief Business Officer PYX-106 Phase 1 trial clinical readout on track for 2H 2024 Expected cash runway i...